Vaccines
25 January 2022
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age13 January 2022
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-3126 January 2022
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine5 January 2022
Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine31 December 2021
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant28 December 2021
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate23 December 2021
Vaxzevria significantly boosted antibody levels against Omicron22 December 2021
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study20 December 2021
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine20 December 2021
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant17 December 2021
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate17 December 2021
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials16 December 2021
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA200115 December 2021
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older11 December 2021
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update8 December 2021
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer’s Disease7 December 2021
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate6 December 2021
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate3 December 2021
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA20012 December 2021
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidatesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports